About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Basal Cell Carcinoma Arisen on Rhinophyma: Report of Four Cases

viagra diskuze

viagra
Giovanni Zabbia, Eliana Gulotta, Daniele Clemente, Pietro Napoli, Massimiliano Tripoli, Bartolo Corradino, Francesco Moschella
From the Plastic and Reconstructive Unit, Department of Surgical Oncologic and Sthomatologic Sciences, University of Palermo. Italy.
Corresponding Author:
Giovanni Zabbia
Email: zabbia.giovanni@libero.it
Received: 10 MAY 2013 Accepted: 15-JUL-2013 Published Online: 30-AUG-2013
DOI: http://dx.doi.org/10.17659/01.2013.0070
Abstract
Rhinophyma is characterized by progressive hyperplasia of nasal sebaceous glands, with fibrosis, follicular plugging and telangiectasias. The term “rhynophyma” derives from the Greek words rhino (meaning nose) and phyma (meaning growth). It is considered the final stage of acne rosacea. Though rare in occurrence, malignant tumors can grow over rhinophymatous skin, with basal cell carcinoma (BCC) being the most commonly reported tumor. Although a rare event, the development of BCC should always be sought in presence of rhinophyma, and also small changes of the skin lesion characteristic that it represent. We report four cases of BCC arising on rhinophyma observed between 1998 and 2012. We recommend the need for a histologic examination of the suspicious lesions or all surgically removed tissue in patients with rhinophyma.
Keywords : Rhinophyma, Basal Cell Carcinoma, Skin Neoplasms, Telangiectasis, Rosacea.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Dec 04, 2024